keyword
https://read.qxmd.com/read/38332245/terbium-149-production-a-focus-on-yield-and-quality-improvement-towards-preclinical-application
#1
JOURNAL ARTICLE
C Favaretto, P V Grundler, Z Talip, U Köster, K Johnston, S D Busslinger, P Sprung, C C Hillhouse, R Eichler, R Schibli, C Müller, N P van der Meulen
Terbium-149 (T1/2  = 4.1 h, Eα  = 3.98 MeV (16.7%), 28 µm range in tissue) is a radionuclide with potential for targeted alpha therapy. Due to the negligible emission of α-emitting daughter nuclides, toxicity to healthy tissue may be reduced in comparison with other α-particle emitters. In this study, terbium-149 was produced via 1.4 GeV proton irradiation of a tantalum target at the CERN-ISOLDE facility. The spallation products were mass separated and implanted on zinc-coated foils and, later, radiochemically processed...
February 8, 2024: Scientific Reports
https://read.qxmd.com/read/36018527/cutting-edge-rare-earth-radiometals-prospects-for-cancer-theranostics
#2
REVIEW
Alexander W E Sadler, Leena Hogan, Benjamin Fraser, Louis M Rendina
BACKGROUND: With recent advances in novel approaches to cancer therapy and imaging, the application of theranostic techniques in personalised medicine has emerged as a very promising avenue of research inquiry in recent years. Interest has been directed towards the theranostic potential of Rare Earth radiometals due to their closely related chemical properties which allow for their facile and interchangeable incorporation into identical bifunctional chelators or targeting biomolecules for use in a diverse range of cancer imaging and therapeutic applications without additional modification, i...
August 26, 2022: EJNMMI Radiopharmacy and Chemistry
https://read.qxmd.com/read/34238164/a-review-on-nuclear-imaging-as-a-promising-modality-for-efficient-diagnosis-of-tuberculosis
#3
REVIEW
Asma Rafique, Rashid Rasheed, Saba Shamim, Munazza Ijaz, Ghulam Murtaza
Tuberculosis (TB) is an infectious disease, which has been declared as a global health issue by the World Health Organization in 1993. Due to the complex pathophysiology of Mycobacterium tuberculosis, it remains a global threat. This article reviews the conventional diagnostic modalities for tuberculosis, their limitations to detect latent TB, multiple drug resistant-TB, human immunodeficiency virus co-infected TB lesions, and TB in children. Moreover, this review illustrates the importance of nuclear medicine imaging for early, non-invasive diagnosis of TB, to detect disease stages and to monitor therapy response...
2022: Current medical imaging
https://read.qxmd.com/read/31780798/alpha-pet-for-prostate-cancer-preclinical-investigation-using-149-tb-psma-617
#4
JOURNAL ARTICLE
Christoph A Umbricht, Ulli Köster, Peter Bernhardt, Nadezda Gracheva, Karl Johnston, Roger Schibli, Nicholas P van der Meulen, Cristina Müller
In this study, it was aimed to investigate 149 Tb-PSMA-617 for targeted α-therapy (TAT) using a mouse model of prostate-specific membrane antigen (PSMA)-expressing prostate cancer. 149 Tb-PSMA-617 was prepared with >98% radiochemical purity (6 MBq/nmol) for the treatment of mice with PSMA-positive PC-3 PIP tumors. 149 Tb-PSMA-617 was applied at 1 × 6 MBq (Day 0) or 2 × 3 MBq (Day 0 & Day 1 or Day 0 & Day 3) and the mice were monitored over time until they had reached a pre-defined endpoint which required euthanasia...
November 28, 2019: Scientific Reports
https://read.qxmd.com/read/31470935/from-bench-to-bedside-the-bad-berka-experience-with-first-in-human-studies
#5
REVIEW
Jingjing Zhang, Aviral Singh, Harshad R Kulkarni, Christiane Schuchardt, Dirk Müller, Hans-J Wester, Theodosia Maina, Frank Rösch, Nicholas P van der Meulen, Cristina Müller, Helmut Mäcke, Richard P Baum
Precision oncology is being driven by rapid advances in novel diagnostics and therapeutic interventions, with treatments targeted to the needs of individual patients on the basis of genetic, biomarker, phenotypic, or psychosocial characteristics that distinguish a given patient from other patients with similar clinical presentations. Inherent in the theranostics paradigm is the assumption that diagnostic test results can precisely determine whether an individual is likely to benefit from a specific treatment...
September 2019: Seminars in Nuclear Medicine
https://read.qxmd.com/read/31346796/preclinical-investigations-and-first-in-human-application-of-152-tb-psma-617-for-pet-ct-imaging-of-prostate-cancer
#6
JOURNAL ARTICLE
Cristina Müller, Aviral Singh, Christoph A Umbricht, Harshad R Kulkarni, Karl Johnston, Martina Benešová, Stefan Senftleben, Dirk Müller, Christiaan Vermeulen, Roger Schibli, Ulli Köster, Nicholas P van der Meulen, Richard P Baum
BACKGROUND: For almost a decade, terbium radioisotopes have been explored for their potential theragnostic application in nuclear medicine: 152 Tb and 155 Tb are the radioisotopes identified for PET or SPECT imaging, while 149 Tb and 161 Tb have suitable decay characteristics for α- and combined β- /Auger-e- -therapy, respectively. In the present study, the application of 152 Tb, in combination with PSMA-617 for imaging of prostate-specific membrane antigen (PSMA)-positive prostate cancer, was demonstrated in a preclinical setting and in a patient with metastatic castration-resistant prostate cancer (mCRPC)...
July 25, 2019: EJNMMI Research
https://read.qxmd.com/read/31231438/quantitative-imaging-of-alpha-emitting-therapeutic-radiopharmaceuticals
#7
REVIEW
Youngho Seo
Targeted alpha therapy (TAT) is an active area of drug development as a highly specific and highly potent therapeutic modality that can be applied to many types of late-stage cancers. In order to properly evaluate its safety and efficacy, understanding biokinetics of alpha-emitting radiopharmaceuticals is essential. Quantitative imaging of alpha-emitting radiopharmaceuticals is often possible via imaging of gammas and positrons produced during complex decay chains of these radionuclides. Analysis of the complex decay chains for alpha-emitting radionuclides (Tb-149, At-211, Bi-212 (decayed from Pb-212), Bi-213, Ra-223, Ac-225, and Th-227) with relevance to imageable signals is attempted in this mini-review article...
June 2019: Nuclear Medicine and Molecular Imaging
https://read.qxmd.com/read/27108447/preclinical-in-vivo-application-of-152-tb-dotanoc-a-radiolanthanide-for-pet-imaging
#8
JOURNAL ARTICLE
Cristina Müller, Christiaan Vermeulen, Karl Johnston, Ulli Köster, Raffaella Schmid, Andreas Türler, Nicholas P van der Meulen
BACKGROUND: Terbium has attracted the attention of researchers and physicians due to the existence of four medically interesting radionuclides, potentially useful for SPECT and PET imaging, as well as for α- and β(-)-radionuclide therapy. The aim of this study was to produce (152)Tb (T 1/2 = 17.5 h, Eβ+av = 1140 keV) and evaluate it in a preclinical setting in order to demonstrate its potential for PET imaging. For this purpose, DOTANOC was used for targeting the somatostatin receptor in AR42J tumor-bearing mice...
December 2016: EJNMMI Research
https://read.qxmd.com/read/23139086/a-unique-matched-quadruplet-of-terbium-radioisotopes-for-pet-and-spect-and-for-%C3%AE-and-%C3%AE-radionuclide-therapy-an-in-vivo-proof-of-concept-study-with-a-new-receptor-targeted-folate-derivative
#9
JOURNAL ARTICLE
Cristina Müller, Konstantin Zhernosekov, Ulli Köster, Karl Johnston, Holger Dorrer, Alexander Hohn, Nico T van der Walt, Andreas Türler, Roger Schibli
UNLABELLED: Terbium offers 4 clinically interesting radioisotopes with complementary physical decay characteristics: (149)Tb, (152)Tb, (155)Tb, and (161)Tb. The identical chemical characteristics of these radioisotopes allow the preparation of radiopharmaceuticals with identical pharmacokinetics useful for PET ((152)Tb) and SPECT diagnosis ((155)Tb) and for α- ((149)Tb) and β(-)-particle ((161)Tb) therapy. The goal of this proof-of-concept study was to produce all 4 terbium radioisotopes and assess their diagnostic and therapeutic features in vivo when labeled with a folate-based targeting agent...
December 2012: Journal of Nuclear Medicine
1
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.